eligibility_summary
Include: Women 18–70 with HER2‑negative inoperable locally advanced/recurrent or metastatic breast cancer, HR+ after endocrine/CDK4/6 failure or chemo‑eligible. Measurable disease, recent biopsy, ECOG 0–1, ≥4‑mo life, adequate organs/heart/lungs, accessible tumor‑draining nodes, fit for camrelizumab+partner, no prior adoptive cell therapy, contraception, washouts. Exclude: rapid progression, active/uncontrolled CNS/effusions/pain, major cardiac/pulmonary disease, active infection (HIV, uncontrolled HBV/HCV, TB), recent thrombosis, other active cancer, pregnancy, autoimmune disease, prior transplant, live vaccine, drug allergy, IL‑2 contraindication, ≥Gr2 neuropathy, recent investigational use, or other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase I, single-arm trial in advanced HER2‑negative breast cancer testing autologous tumor‑draining lymph node–derived lymphocytes (LNLs) with combination therapy. Interventions: LN surgery, cyclophosphamide (alkylating) + fludarabine (purine antimetabolite) for non‑myeloablative lymphodepletion, single‑infusion LNL adoptive cell therapy, interleukin‑2 (cytokine) support, camrelizumab (anti‑PD‑1 mAb), plus investigator‑chosen chemotherapy, antibody‑drug conjugate (ADC), or PARP inhibitor. Mechanisms/targets: LNLs supply tumor‑reactive T cells, lymphodepletion reduces endogenous lymphocytes/Tregs and creates homeostatic space, IL‑2 expands/activates transferred T cells, camrelizumab blocks PD‑1/PD‑L1 to reverse T‑cell dysfunction, ADCs bind tumor antigens to deliver cytotoxics, PARP inhibitors block DNA repair (synthetic lethality), chemotherapy induces DNA damage/cell death.